Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
- Resource Type
- Article
- Source
- In
ESMO Open October 2022 7(5) - Subject
- Language
- ISSN
- 2059-7029